Compare Honeywell International Inc (HON) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Honeywell International Inc trades at $208.11 (market cap $65.70B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Honeywell International Inc is far larger — about 13.5× Travere Therapeutics Inc. Common Stock's market cap, and Honeywell International Inc pays a 1.35% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HON | TVTX | |
|---|---|---|
Market Cap | $65.70B | $4.88B |
Volume | 1,861,268 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $248.79 | $67.52 |
52-Week Low | $188.14 | $26.79 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $90.49B | $5.01B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $207.61, down 0.97% on the day, as technical indicators show bearish momentum despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.95 exceeding expectations of $1.83. Recent news highlights Honeywell's $300 million contract win for the Dangote refinery project and the company's strategic focus on automation following its corporate restructuring into three separate entities.
Honeywell presents a compelling value opportunity with attractive valuation multiples (P/E of 7.97, EV/EBITDA of 6.74) and strong profitability metrics (ROE 47.43%, net margin 21.58%). However, investors face risks from increasing debt levels and the execution challenges of the corporate spin-off strategy. Analyst consensus remains bullish with a $259.25 price target representing 25% upside potential from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
